How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

What happened Security researchers disclosed multiple vulnerabilities affecting Apple AirDrop and Google and Samsung Quick Share that could allow attackers within wireless range to crash or disrupt ...

As organizations race to adopt artificial intelligence, the conversation has increasingly shifted from raw model performance to a more practical question: how can enterprises run AI at lower cost ...

In the AI value chain, application-layer leaders like Palantir and ServiceNow may win long term as chip/cloud margins ...

Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and ...

Buffer overflow vulnerabilities have driven remote code execution for decades and keep appearing in critical network ...

On Wednesday, OpenAI took its biggest step yet towards full technological independence with the unveiling of a new AI chip, ...

Autonomous AI post-training reached frontier scale for the first time: NVIDIA researchers published a paper showing an AI ...

The most capable one didn't make the cut.

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

LinkDaddy® has expanded Cloud Authority Backlinks, a multi-cloud SEO system that delivers DoFollow backlinks, ...